---
title: "BUZZ-Amgen up after quarterly results beat Wall Street estimates"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274713786.md"
description: "Shares of Amgenrose 1.7% to $343.99 in after-hours trading following a strong quarterly performance. The company reported a 9% increase in revenue to $9.9 billion, surpassing analyst expectations of $9.5 billion. Adjusted earnings per share for Q4 were $5.29, exceeding the forecast of $4.73. Amgen anticipates adjusted earnings per share of $21.60 to $23.00 for 2026, with annual revenue projected between $37 billion and $38.4 billion, above the $37.1 billion estimate from analysts. The stock has increased by 3.5% in 2025."
datetime: "2026-02-03T21:25:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274713786.md)
  - [en](https://longbridge.com/en/news/274713786.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274713786.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274713786.md) | [繁體中文](https://longbridge.com/zh-HK/news/274713786.md)


# BUZZ-Amgen up after quarterly results beat Wall Street estimates

Shares of Amgen (AMGN.O) up 1.7% at $343.99 in after-hours trading

AMGN reports quarterly revenue rises 9% from a year earlier to $9.9 billion, beating the average analyst estimate of $9.5 billion, according to LSEG data

It posts Q4 adjusted earnings per share at $5.29, exceeding analysts’ expectations of $4.73

Amgen expects 2026 adjusted earnings per share of $21.60 to $23.00, while Wall Street estimates it to be $22.09 per share

Co forecast annual revenue to be in the range of $37 billion to $38.4 billion, with a midpoint well ahead of analysts’ forecast of $37.1 billion

Stock has been up 3.5% in 2025

### Related Stocks

- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [Amgen Inc. (AMGN.US)](https://longbridge.com/en/quote/AMGN.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [Dimensional Fund Advisors LP Raises Holdings in Amgen Inc. $AMGN](https://longbridge.com/en/news/277759831.md)
- [BUZZ-MAIA Biotechnology plunges after $30 million share sale](https://longbridge.com/en/news/277605454.md)
- [Kyowa Kirin discontinues ongoing trials of rocatinlimab](https://longbridge.com/en/news/277766830.md)
- [Veeva Systems Q4 revenue eases past estimates](https://longbridge.com/en/news/277834275.md)
- [Xeris Biopharma Q4 product revenue beats analyst expectations, driven by higher patient demand](https://longbridge.com/en/news/277460502.md)